Late Tuesday, Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of $3.92 per share on $607.58 million in sales for its first quarter. In response, Jazz stock was untouched.
On average, analysts surveyed by FactSet expected Jazz earnings of $3.73 per share, excluding some items, and $609.3 million in sales.
In the year-earlier period, Jazz reported earnings of 45 cents per share and $534.73 million in sales.
For the year, Jazz reaffirmed its guidance for $2.55 billion to $2.7 billion in revenue. Analysts called for Jazz earnings of $15.76 per share and $2.66 billion in revenue. Jazz is currently working to buy GW Pharmaceuticals (GWPH).
In after-hours trading on the stock market today, Jazz stock wasn’t active. Shares closed down 3% at 160.20 during the regular session.
More to follow.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE: